JPWO2020219681A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020219681A5 JPWO2020219681A5 JP2021562989A JP2021562989A JPWO2020219681A5 JP WO2020219681 A5 JPWO2020219681 A5 JP WO2020219681A5 JP 2021562989 A JP2021562989 A JP 2021562989A JP 2021562989 A JP2021562989 A JP 2021562989A JP WO2020219681 A5 JPWO2020219681 A5 JP WO2020219681A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- antibody
- acid sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 82
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 26
- 210000004027 cell Anatomy 0.000 claims 23
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 20
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 15
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 14
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 13
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 13
- 238000000533 capillary isoelectric focusing Methods 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 10
- 229940068968 polysorbate 80 Drugs 0.000 claims 10
- 229920000053 polysorbate 80 Polymers 0.000 claims 10
- 239000002552 dosage form Substances 0.000 claims 9
- 229960002885 histidine Drugs 0.000 claims 9
- 229930006000 Sucrose Natural products 0.000 claims 8
- 230000002378 acidificating effect Effects 0.000 claims 8
- 235000001014 amino acid Nutrition 0.000 claims 8
- 210000000822 natural killer cell Anatomy 0.000 claims 8
- 239000005720 sucrose Substances 0.000 claims 8
- 102000052645 human CD38 Human genes 0.000 claims 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 6
- 108020003175 receptors Proteins 0.000 claims 6
- 102000005962 receptors Human genes 0.000 claims 6
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims 4
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 241000699670 Mus sp. Species 0.000 claims 3
- 229940024606 amino acid Drugs 0.000 claims 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 3
- NPWMTBZSRRLQNJ-VKHMYHEASA-N (3s)-3-aminopiperidine-2,6-dione Chemical group N[C@H]1CCC(=O)NC1=O NPWMTBZSRRLQNJ-VKHMYHEASA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 229960004793 sucrose Drugs 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 102000057266 human FCGR3A Human genes 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837518P | 2019-04-23 | 2019-04-23 | |
| US62/837,518 | 2019-04-23 | ||
| US201962859699P | 2019-06-10 | 2019-06-10 | |
| US62/859,699 | 2019-06-10 | ||
| EP20305146 | 2020-02-17 | ||
| EP20305146.1 | 2020-02-17 | ||
| EP20305145 | 2020-02-17 | ||
| EP20305145.3 | 2020-02-17 | ||
| PCT/US2020/029531 WO2020219681A1 (en) | 2019-04-23 | 2020-04-23 | Anti-cd38 antibodies and formulations |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022529502A JP2022529502A (ja) | 2022-06-22 |
| JPWO2020219681A5 true JPWO2020219681A5 (https=) | 2023-05-01 |
| JP2022529502A5 JP2022529502A5 (https=) | 2023-05-01 |
| JP7602485B2 JP7602485B2 (ja) | 2024-12-18 |
Family
ID=70739160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562989A Active JP7602485B2 (ja) | 2019-04-23 | 2020-04-23 | 抗ｃｄ３８抗体および製剤 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3958898A1 (https=) |
| JP (1) | JP7602485B2 (https=) |
| KR (1) | KR20220003562A (https=) |
| CN (2) | CN114269375A (https=) |
| AU (1) | AU2020261039A1 (https=) |
| BR (1) | BR112021021060A2 (https=) |
| CA (1) | CA3137365A1 (https=) |
| CO (1) | CO2021015462A2 (https=) |
| IL (1) | IL287477A (https=) |
| MA (1) | MA55761A (https=) |
| MX (1) | MX2021012967A (https=) |
| MY (1) | MY206426A (https=) |
| SG (1) | SG11202111602YA (https=) |
| TW (1) | TWI878289B (https=) |
| WO (1) | WO2020219681A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023109928A1 (zh) * | 2021-12-16 | 2023-06-22 | 上海宝济药业有限公司 | 抗免疫球蛋白降解酶酶切的Fc变体 |
| WO2024023843A1 (en) * | 2022-07-26 | 2024-02-01 | Dr. Reddy’S Laboratories Limited | A pharmaceutical formulation of a therapeuticantibody and preparations thereof |
| WO2025245526A1 (en) * | 2024-05-24 | 2025-11-27 | Research Institute At Nationwide Children's Hospital | Cd-38 protein binding compositions and methods related thereto |
| CN120535629B (zh) * | 2025-04-22 | 2026-01-23 | 西安市中心血站（陕西省血液中心） | 一种用于抑制cd38单抗对输血相容性检测干扰的抗体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005016683D1 (de) | 2004-07-10 | 2009-10-29 | Fox Chase Cancer Ct | Genetisch modifizierte, menschliche, natürliche killerzellenlinien: |
| CN103172731A (zh) * | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| SG10201603411WA (en) * | 2011-10-28 | 2016-07-28 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| US10617757B2 (en) * | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| DK3827845T3 (da) * | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| GEP20217249B (en) * | 2016-06-30 | 2021-04-26 | Inc Celltrion | Stable liquid pharmaceutical preparation |
| SG11201910134SA (en) * | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| WO2019064263A1 (en) * | 2017-09-29 | 2019-04-04 | Janssen Biotech, Inc. | NOVEL FORMULATIONS FOR STABILIZING LOW DOSE ANTIBODY COMPOSITIONS |
| CN108752475B (zh) * | 2018-06-14 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人cd38抗体及其用途 |
-
2020
- 2020-04-23 TW TW109113639A patent/TWI878289B/zh active
- 2020-04-23 MY MYPI2021006312A patent/MY206426A/en unknown
- 2020-04-23 MX MX2021012967A patent/MX2021012967A/es unknown
- 2020-04-23 CA CA3137365A patent/CA3137365A1/en active Pending
- 2020-04-23 MA MA055761A patent/MA55761A/fr unknown
- 2020-04-23 WO PCT/US2020/029531 patent/WO2020219681A1/en not_active Ceased
- 2020-04-23 SG SG11202111602YA patent/SG11202111602YA/en unknown
- 2020-04-23 CN CN202080030148.3A patent/CN114269375A/zh active Pending
- 2020-04-23 EP EP20726267.6A patent/EP3958898A1/en active Pending
- 2020-04-23 JP JP2021562989A patent/JP7602485B2/ja active Active
- 2020-04-23 BR BR112021021060A patent/BR112021021060A2/pt unknown
- 2020-04-23 KR KR1020217037641A patent/KR20220003562A/ko not_active Ceased
- 2020-04-23 CN CN202510964194.5A patent/CN120757645A/zh active Pending
- 2020-04-23 AU AU2020261039A patent/AU2020261039A1/en active Pending
-
2021
- 2021-10-21 IL IL287477A patent/IL287477A/en unknown
- 2021-11-17 CO CONC2021/0015462A patent/CO2021015462A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12527843B2 (en) | Immune-cell targeted bispecific chimeric proteins and uses thereof | |
| RU2748024C2 (ru) | Составы на основе антитела к CD19 | |
| CN104902914B (zh) | 高纯度和优异产量的正确折叠的依那西普 | |
| KR102171669B1 (ko) | 조합물 및 이의 용도 | |
| US10858425B2 (en) | Pan-ELR+ CXC chemokine antibodies | |
| US20120045445A1 (en) | Method of treating viral diseases | |
| EP3411398A2 (en) | Targeted therapeutic agents and uses thereof | |
| CA2901468C (en) | Pan-elr+ cxc chemokine antibodies | |
| US20220177550A1 (en) | Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3) | |
| KR20200033302A (ko) | Nkg2d, cd16 및 flt3에 결합하는 단백질 | |
| CN115666649B (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| KR20210078473A (ko) | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 | |
| CN114762678B (zh) | 抗tigit抗体药物组合物及其用途 | |
| DE60127237T2 (de) | Therapeutischer monoklonaler rekombinanter anti-ige antikörper gegen hunde-allergie | |
| RS63238B1 (sr) | Kombinovana terapija sa anti-cd19 antitelom i azotnim senfom | |
| CN114652825A (zh) | 稳定的抗体制剂及其制备方法和应用 | |
| CN114555117A (zh) | 抗cd20抗体制剂及抗cd20抗体在治疗cd20阳性疾病中的应用 | |
| JPWO2020219681A5 (https=) | ||
| CN119095584A (zh) | 抗gm-csf抗体的液体药物配制品及其用途 | |
| RU2021133923A (ru) | Антитела к cd38 и составы | |
| US20260115254A1 (en) | Immune-cell targeted bispecific chimeric proteins and uses thereof | |
| CN1291998C (zh) | Nkg2d受体的配体及其应用 | |
| CN1128810C (zh) | 防治肝病的鲨鱼肝多肽结构及纯化 | |
| WO2018178594A1 (fr) | Prévention d'une infection par le virus respiratoire syncytial dans les voies respiratoires supérieures | |
| WO1993002692A1 (en) | Method of combatting hiv infections |